ストックスクリーナーアプリを入手
20.62
16.33%
2.895
プレマーケット:
20.04
-0.58
-2.81%
Summit Therapeutics Inc (SMMT) 最新ニュース
Why is Summit stock in selloff after late-stage trial data for lead asset? - MSN
Summit Therapeutics: What's This Ivonescimab Rollercoaster - Nasdaq
10 Stocks Leaving Wall Street in The Dust - Insider Monkey
Truist Sticks to $35 Target on Summit (SMMT) Despite Shifting Deal Landscape - Insider Monkey
Explaining Summit's Fall Despite Positive Data In EGFR-Positive Lung Cancer (NASDAQ:SMMT) - Seeking Alpha
Why Summit Therapeutics Inc. (SMMT) Crashed Last Week - MSN
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround - Yahoo Finance
Summit Therapeutics: Market Overreaction Creates Opportunity (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results - sharewise
Summit Therapeutics (SMMT) Gains Attention Following Positive Phase III Trial Results | SMMT Stock News - GuruFocus
SMMT: Summit Therapeutics' Market Outperform Rating Reiterated by JMP Securities | SMMT Stock News - GuruFocus
SMMT, MTDR, FTAI: 3 High-Potential Russell 2000 Stocks with Strong Buy Ratings - TipRanks
Is SMMT Stock A Buy After Its Recent Plunge? - Forbes
Summit Therapeutics: What’s This Ivonescimab Rollercoaster - Trefis
3 No-Brainer Healthcare Stocks to Buy in June - AOL.com
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? - AOL.com
Five things for pharma marketers to know: Monday, June 2, 2025 - Medical Marketing and Media
These 10 Stocks Just Rocked The Market - Insider Monkey
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio? - Benzinga
Why Summit Therapeutics Inc. (SMMT) Crashed On Friday - Insider Monkey
Summit Therapeutics Announces Positive Phase III Trial Results - TipRanks
U.S. Markets Ended Friday Mixed As Ulta Beauty Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Faces Setback After Trial Results - GuruFocus
Summit Therapeutics (SMMT) Stock Plunges on Trial Data Release - GuruFocus
Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release - Seeking Alpha
Summit stock in selloff post cancer trial data (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics (SMMT) Advances Lung Cancer Drug with Positi - GuruFocus
Why Summit Therapeutics Plunged Today - Yahoo Finance
Summit Therapeutics: Critical NSCLC Study Readout Jeopardizes Ivonesimab Approval (SMMT) - Seeking Alpha
Summit's Shares Fall Despite Progression-Free Survival Gains in Ivonescimab Trial - marketscreener.com
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation By Stocktwits - Investing.com India
Summit’s disappointing survival readout raises stakes for full data - Endpoints News
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation - MSN
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down. - Barron's
Summit Says Ivonescimab Significantly Improves Progression-Free Survival; Overall Survival Trend Not Statistically Significant -- Shares Drop - marketscreener.com
Akeso, Summit's ivonescimab delayed progression of certain lung cancers in first global phase 3 readout - Fierce Pharma
Summit Therapeutics Reports Mixed Trial Results for Ivonescimab in Lung Cancer Treatment - geneonline.com
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint - Benzinga
Summit stock down after cancer trial data (update) (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics stock dips after clinical trial results - Investing.com
Summit Therapeutics stock dips after clinical trial results By Investing.com - Investing.com UK
Summit shrugs off survival miss with its VEGF bispecific - Pharmaphorum
Summit Therapeutics (SMMT): Ivonescimab Plus Chemo Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients with EGFR-Mutant NSCLC - StreetInsider
Summit shows mixed results from key study of lung cancer drug - statnews.com
Summit Therapeutics (SMMT) Reveals Promising Phase III Trial Out - GuruFocus
Summit Therapeutics (SMMT) Surges Following HARMONi Trial Result - GuruFocus
Summit Therapeutics Inc. Announces Topline Results from the Phase III Clinical Trial, Harmoni - marketscreener.com
Summit Therapeutics Stock Dips Despite Trial Success - TipRanks
Summit Therapeutics (SMMT) Surges Following HARMONi Trial Results | SMMT Stock News - GuruFocus
Summit Therapeutics (SMMT) Reveals Promising Phase III Trial Outcomes for Ivonescimab | SMMT Stock News - GuruFocus
Summit Therapeutics announces topline results from Phase 3 HARMONi trial - TipRanks
Summit Therapeutics: Buy Rating Backed by Promising Ivonescimab Trial and Favorable PFS Outcomes - TipRanks
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study - Yahoo Finance
Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com
Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect? - Yahoo Finance
3 High-Flying Stocks That Could Soar Even More - Yahoo Finance
Summit Therapeutics (NasdaqGM:SMMT) Reports US$63M Net Loss For Q1 2025 - simplywall.st
Summit Therapeutics (SMMT) Receives Buy Rating and $33 Target | - GuruFocus
Summit Therapeutics (SMMT) Receives Buy Rating and $33 Target | SMMT Stock News - GuruFocus
0.87%
0.19%
大文字化:
|
ボリューム (24 時間):